Month: August 2022

Aug 09 2022

Uncategorized

Karuna’s experimental schizophrenia drug succeeds in advanced study

by Clinical Editor

No Comments

If approved by the FDA, the Boston biotech’s medicine would be the first new type of treatment for the disease in decades.

Aug 09 2022

Uncategorized

Long-acting injectables remain under-utilised for schizophrenia in 7 major markets despite benefits: GlobalData

by Clinical Editor

No Comments

According to GlobalData, there are many reasons for lingering resistance around the use of LAIs over oral antipsychotics, with individual preferences from both patients and psychiatrists.

Aug 09 2022

Uncategorized

The Importance of Sexual Health in People with Schizophrenia

by Clinical Editor

No Comments

Cultural myth leads us to believe the sexual health of patients with schizophrenia is unimportant. Data show the contrary is true, given the high rates of STI and sexual dysfunction....

Aug 09 2022

Uncategorized

Karuna’s Schizophrenia-Trial Data Are ‘Best Case Scenario’ for the Biotech Stock

by Clinical Editor

No Comments

New data from Karuna Therapeutics on the schizophrenia treatment KarXT sent shares of the biotech up more than 60% as analysts said the results were strong enough that the drug...

Aug 08 2022

Uncategorized

Karuna Therapeutics’ schizophrenia drug achieves study goals, heralding new treatment approach

by Clinical Editor

No Comments

Karuna Therapeutics said that a novel combination pill reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage trial.

Aug 08 2022

Uncategorized

The Importance of Sexual Health in People with Schizophrenia

by Clinical Editor

No Comments

Cultural myth leads us to believe the sexual health of patients with schizophrenia is unimportant. Data show the contrary is true, given the high rates of STI and sexual dysfunction....

Aug 08 2022

Uncategorized

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

by Clinical Editor

No Comments

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological …

Aug 08 2022

Uncategorized

Karuna Therapeutics Sees Positive Results in Phase 3 Trial for Schizophrenia Treatment

by Clinical Editor

No Comments

By Chris Wack Karuna Therapeutics Inc. said Monday it saw positive topline results from its Phase 3 trial evaluating the efficacy, safety and tolerability …

Aug 08 2022

Uncategorized

Karuna Therapeutics jumps 38% as schizophrenia trial meets key goals

by Clinical Editor

No Comments

The shares of Karuna Therapeutics (KRTX) surged ~38% in the pre-market on Monday after the clinical-stage biotech announced that its late-stage trial for experimental …

Aug 07 2022

Uncategorized

The Importance of Sexual Health in People with Schizophrenia

by Clinical Editor

No Comments

Cultural myth leads us to believe the sexual health of patients with schizophrenia is unimportant. Data show the contrary is true, given the high rates of STI and sexual dysfunction....